Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Tokyo - Delayed Quote JPY

WIN-Partners Co., Ltd. (3183.T)

Compare
1,292.00
+47.00
+(3.78%)
At close: April 18 at 3:30:00 PM GMT+9
Loading Chart for 3183.T
  • Previous Close 1,245.00
  • Open 1,255.00
  • Bid 1,282.00 x --
  • Ask 1,297.00 x --
  • Day's Range 1,255.00 - 1,295.00
  • 52 Week Range 1,012.00 - 1,595.00
  • Volume 21,000
  • Avg. Volume 46,708
  • Market Cap (intraday) 36.938B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 18.62
  • EPS (TTM) 69.38
  • Earnings Date May 15, 2025
  • Forward Dividend & Yield 104.00 (8.05%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est --

WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters; pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters; and stent grafts, transcatheter heart valves, and mechanical heart valves. It also provides peripheral vascular stents, carotid artery stents, and embolic coils; and insulin pumps, as well as continuous glucose monitoring, and computed tomography equipment. WIN-Partners Co., Ltd. was founded in 1973 and is headquartered in Tokyo, Japan.

www.win-partners.co.jp

629

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 3183.T

View More

Performance Overview: 3183.T

Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

3183.T
2.08%
Nikkei 225 (^N225)
12.94%

1-Year Return

3183.T
14.10%
Nikkei 225 (^N225)
8.80%

3-Year Return

3183.T
46.18%
Nikkei 225 (^N225)
29.59%

5-Year Return

3183.T
68.65%
Nikkei 225 (^N225)
74.55%

Compare To: 3183.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3183.T

View More

Valuation Measures

Annual
As of 4/18/2025
  • Market Cap

    36.94B

  • Enterprise Value

    21.09B

  • Trailing P/E

    18.64

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.46

  • Price/Book (mrq)

    1.62

  • Enterprise Value/Revenue

    0.26

  • Enterprise Value/EBITDA

    6.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.48%

  • Return on Assets (ttm)

    4.11%

  • Return on Equity (ttm)

    8.82%

  • Revenue (ttm)

    82.61B

  • Net Income Avi to Common (ttm)

    2.05B

  • Diluted EPS (ttm)

    69.38

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.54B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 3183.T

View More

Company Insights: 3183.T

Research Reports: 3183.T

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.